Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations

박병우

January 2014

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy r...

Effect of genetic variability in 20 pharmacogenes on concentrations of tamoxifen and its metabolites

Chen, Yuanhuang
Marcath, Lauren A.
Eliassen, Finn Magnus
Lende, Tone Hoel
Soiland, Havard
Mellgren, Gunnar
Helland, Thomas
Hertz, Daniel Louis

January 2021

Background: Tamoxifen, as a treatment of estrogen receptor positive (ER+) breast cancer, is a weak a...

Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping

Binkhorst, Lisette
Mathijssen, Ron
Jager, Agnes
Gelder, Teun

January 2015

Clinical response to tamoxifen varies widely among women treated with this drug for hormone receptor...

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

Irvin, William J.
Walko, Christine M.
Weck, Karen E.
Ibrahim, Joseph G.
Chiu, Wing K.
Dees, E. Claire
Moore, Susan G.
Olajide, Oludamilola A.
Graham, Mark L.
Canale, Sean T.
Raab, Rachel E.
Corso, Steven W.
Peppercorn, Jeffrey M.
Anderson, Steven M.
Friedman, Kenneth J.
Ogburn, Evan T.
Desta, Zeruesenay
Flockhart, David A.
McLeod, Howard L.
Evans, James P.
Carey, Lisa A.

January 2011

We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and inves...

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity

Hertz, Daniel L.
Deal, Allison
Ibrahim, Joseph G.
Walko, Christine M.
Weck, Karen E.
Anderson, Steven
Magrinat, Gustav
Olajide, Oludamilola
Moore, Susan
Raab, Rachel
Carrizosa, Daniel R.
Corso, Steven
Schwartz, Garry
Graham, Mark
Peppercorn, Jeffrey M.
Jones, David R.
Desta, Zeruesenay
Flockhart, David A.
Evans, James P.
McLeod, Howard L.
Carey, Lisa A.
Irvin, William J.

January 2016

Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We p...

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity

Hertz, Daniel L.
Deal, Allison
Ibrahim, Joseph G.
Walko, Christine M.
Weck, Karen E.
Anderson, Steven
Magrinat, Gustav
Olajide, Oludamilola
Moore, Susan
Raab, Rachel
Carrizosa, Daniel R.
Corso, Steven
Schwartz, Garry
Graham, Mark
Peppercorn, Jeffrey M.
Jones, David R.
Desta, Zeruesenay
Flockhart, David A.
Evans, James P.
McLeod, Howard L.
Carey, Lisa A.
Irvin, William J.

January 2016

Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We p...

Impact of tamoxifen dose on tamoxifen and its active metabolites exposure in breast cancer patients: preliminary results from a prospective, open-label trial

Dahmane, E.
Zaman, K.
Galmiche Rindisbacher, M.
Berthod, G.
Perey, L.
Bodmer, A.
Leyvraz, S.
Eap, C.
Decosterd, L.
Buclin, T.
Csajka, C.

January 2012

Background: CYP2D6 is the key enzyme responsible for tamoxifen bioactivation mainly into endoxifen. ...

Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment

Marcath, L.A.
Deal, A.M.
Van Wieren, E.
Danko, W.
Walko, C.M.
Ibrahim, J.G.
Weck, K.E.
Jones, D.R.
Desta, Z.
McLeod, H.L.
Carey, L.A.
Irvin, W.J., Jr.
Hertz, D.L.

January 2017

Objectives Tamoxifen bioactivation to endoxifen is mediated primarily by CYP2D6; however, considerab...

Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype

Martínez de Dueñas, Eduardo
Ochoa Aranda, Enrique
Blancas López-Barajas, Isabel
Ferrer Magdalena, Teresa
Bandrés Moya, Fernando
Chicharro García, Luis Miguel
Gómez Capilla, José A.
Zafra Ceres, Mercedes
Haro, Tomás de
Romero Llorens, Regina
Ferrer Albiach, Carlos
Ferriols Lisart, Rafael
Chover Lara, Dolores
López Rodríguez, Ángela
Munárriz Ferrandis, Javier
Olmos Antón, Santiago

January 2014

CYP2D6 is a key enzyme in tamoxifen metabolism, transforming it into its main activemetabolite, endo...

The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity

Welzen, M.E.B.
Dezentje, V.O.
Schaik, R.H. van
Colbers, A.P.
Guchelaar (LUMC), H.J.
Erp, N. van
Hartigh, J. den
Burger, D.M.
Laarhoven, H.W. van

January 2015

BACKGROUND: The effect of tamoxifen dose elevation on endoxifen serum concentration was investigated...

CYP2D6 genotype and adjuvant tamoxifen:meta-analysis of heterogeneous study populations

Province, M. A.
Goetz, M. P.
Brauch, H.
Flockhart, D. A.
Hebert, J. M.
Whaley, R.
Suman, V. J.
Schroth, W.
Winter, S.
Zembutsu, H.
Mushiroda, T.
Newman, W. G.
Lee, M-T M.
Ambrosone, C. B.
Beckmann, M. W.
Choi, J-Y
Dieudonné, A-S
Fasching, P. A.
Ferraldeschi, R.
Gong, L.
Haschke-Becher, E.
Howell, A
Jordan, L. B.
Hamann, U.
Kiyotani, K.
Krippl, P.
Lambrechts, D.
Latif, A
Langsenlehner, U.
Lorizio, W.
Neven, P.
Nguyen, A. T.
Park, B-W
Purdie, C. A.
Quinlan, P.
Renner, W.
Schmidt, M.
Schwab, M.
Shin, J-G
Stingl, J. C.
Wegman, P.
Wingren, S.
Wu, A. H. B.
Ziv, E.
Zirpoli, G.
Thompson, A. M.
Jordan, V. C.
Nakamura, Y.
Altman, R. B.
Ames, M. M.
Weinshilboum, R. M.
Eichelbaum, M.
Ingle, J. N.
Klein, T. E.

February 2014

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy r...

CYP2D6 genotype and adjuvant tamoxifen:meta-analysis of heterogeneous study populations

Province, M. A.
Goetz, M. P.
Brauch, H.
Flockhart, D. A.
Hebert, J. M.
Whaley, R.
Suman, V. J.
Schroth, W.
Winter, S.
Zembutsu, H.
Mushiroda, T.
Newman, W. G.
Lee, M-T M.
Ambrosone, C. B.
Beckmann, M. W.
Choi, J-Y
Dieudonné, A-S
Fasching, P. A.
Ferraldeschi, R.
Gong, L.
Haschke-Becher, E.
Howell, A
Jordan, L. B.
Hamann, U.
Kiyotani, K.
Krippl, P.
Lambrechts, D.
Latif, A
Langsenlehner, U.
Lorizio, W.
Neven, P.
Nguyen, A. T.
Park, B-W
Purdie, C. A.
Quinlan, P.
Renner, W.
Schmidt, M.
Schwab, M.
Shin, J-G
Stingl, J. C.
Wegman, P.
Wingren, S.
Wu, A. H. B.
Ziv, E.
Zirpoli, G.
Thompson, A. M.
Jordan, V. C.
Nakamura, Y.
Altman, R. B.
Ames, M. M.
Weinshilboum, R. M.
Eichelbaum, M.
Ingle, J. N.
Klein, T. E.

February 2014

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy r...

CYP2D6 genotype and adjuvant tamoxifen:meta-analysis of heterogeneous study populations

Province, M. A.
Goetz, M. P.
Brauch, H.
Flockhart, D. A.
Hebert, J. M.
Whaley, R.
Suman, V. J.
Schroth, W.
Winter, S.
Zembutsu, H.
Mushiroda, T.
Newman, W. G.
Lee, M-T M.
Ambrosone, C. B.
Beckmann, M. W.
Choi, J-Y
Dieudonné, A-S
Fasching, P. A.
Ferraldeschi, R.
Gong, L.
Haschke-Becher, E.
Howell, A
Jordan, L. B.
Hamann, U.
Kiyotani, K.
Krippl, P.
Lambrechts, D.
Latif, A
Langsenlehner, U.
Lorizio, W.
Neven, P.
Nguyen, A. T.
Park, B-W
Purdie, C. A.
Quinlan, P.
Renner, W.
Schmidt, M.
Schwab, M.
Shin, J-G
Stingl, J. C.
Wegman, P.
Wingren, S.
Wu, A. H. B.
Ziv, E.
Zirpoli, G.
Thompson, A. M.
Jordan, V. C.
Nakamura, Y.
Altman, R. B.
Ames, M. M.
Weinshilboum, R. M.
Eichelbaum, M.
Ingle, J. N.
Klein, T. E.

February 2014

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy r...

The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity

Welzen, MEB
Dezentje, VO
van Schaik, Ron
Colbers, APH
Guchelaar, HJ
van Erp, NP
den Hartigh, J
Burger, DM
van Laarhoven, HWM

January 2015

Background: The effect of tamoxifen dose elevation on endoxifen serum concentration was investigated...

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects

Dezentjé, V O
Opdam, F L
Gelderblom, H
Hartigh den, J
Van der Straaten, T
Vree, R
Maartense, E
Smorenburg, C H
Putter, H
Dieudonné, A S
Neven, Patrick
Van de Velde, C J H
Nortier, J W R
Guchelaar, H-J

October 2015

Breast cancer patients with absent or reduced CYP2D6 activity and consequently low endoxifen levels ...

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations

박병우

January 2014

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy r...

Effect of genetic variability in 20 pharmacogenes on concentrations of tamoxifen and its metabolites

Chen, Yuanhuang
Marcath, Lauren A.
Eliassen, Finn Magnus
Lende, Tone Hoel
Soiland, Havard
Mellgren, Gunnar
Helland, Thomas
Hertz, Daniel Louis

January 2021

Background: Tamoxifen, as a treatment of estrogen receptor positive (ER+) breast cancer, is a weak a...

Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping

Binkhorst, Lisette
Mathijssen, Ron
Jager, Agnes
Gelder, Teun

January 2015

Clinical response to tamoxifen varies widely among women treated with this drug for hormone receptor...

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

Irvin, William J.
Walko, Christine M.
Weck, Karen E.
Ibrahim, Joseph G.
Chiu, Wing K.
Dees, E. Claire
Moore, Susan G.
Olajide, Oludamilola A.
Graham, Mark L.
Canale, Sean T.
Raab, Rachel E.
Corso, Steven W.
Peppercorn, Jeffrey M.
Anderson, Steven M.
Friedman, Kenneth J.
Ogburn, Evan T.
Desta, Zeruesenay
Flockhart, David A.
McLeod, Howard L.
Evans, James P.
Carey, Lisa A.

January 2011

We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and inves...

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity

Hertz, Daniel L.
Deal, Allison
Ibrahim, Joseph G.
Walko, Christine M.
Weck, Karen E.
Anderson, Steven
Magrinat, Gustav
Olajide, Oludamilola
Moore, Susan
Raab, Rachel
Carrizosa, Daniel R.
Corso, Steven
Schwartz, Garry
Graham, Mark
Peppercorn, Jeffrey M.
Jones, David R.
Desta, Zeruesenay
Flockhart, David A.
Evans, James P.
McLeod, Howard L.
Carey, Lisa A.
Irvin, William J.

January 2016

Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We p...

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity

Hertz, Daniel L.
Deal, Allison
Ibrahim, Joseph G.
Walko, Christine M.
Weck, Karen E.
Anderson, Steven
Magrinat, Gustav
Olajide, Oludamilola
Moore, Susan
Raab, Rachel
Carrizosa, Daniel R.
Corso, Steven
Schwartz, Garry
Graham, Mark
Peppercorn, Jeffrey M.
Jones, David R.
Desta, Zeruesenay
Flockhart, David A.
Evans, James P.
McLeod, Howard L.
Carey, Lisa A.
Irvin, William J.

January 2016

Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We p...

Impact of tamoxifen dose on tamoxifen and its active metabolites exposure in breast cancer patients: preliminary results from a prospective, open-label trial

Dahmane, E.
Zaman, K.
Galmiche Rindisbacher, M.
Berthod, G.
Perey, L.
Bodmer, A.
Leyvraz, S.
Eap, C.
Decosterd, L.
Buclin, T.
Csajka, C.

January 2012

Background: CYP2D6 is the key enzyme responsible for tamoxifen bioactivation mainly into endoxifen. ...

Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment

Marcath, L.A.
Deal, A.M.
Van Wieren, E.
Danko, W.
Walko, C.M.
Ibrahim, J.G.
Weck, K.E.
Jones, D.R.
Desta, Z.
McLeod, H.L.
Carey, L.A.
Irvin, W.J., Jr.
Hertz, D.L.

January 2017

Objectives Tamoxifen bioactivation to endoxifen is mediated primarily by CYP2D6; however, considerab...

Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype

Martínez de Dueñas, Eduardo
Ochoa Aranda, Enrique
Blancas López-Barajas, Isabel
Ferrer Magdalena, Teresa
Bandrés Moya, Fernando
Chicharro García, Luis Miguel
Gómez Capilla, José A.
Zafra Ceres, Mercedes
Haro, Tomás de
Romero Llorens, Regina
Ferrer Albiach, Carlos
Ferriols Lisart, Rafael
Chover Lara, Dolores
López Rodríguez, Ángela
Munárriz Ferrandis, Javier
Olmos Antón, Santiago

January 2014

CYP2D6 is a key enzyme in tamoxifen metabolism, transforming it into its main activemetabolite, endo...

The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity

Welzen, M.E.B.
Dezentje, V.O.
Schaik, R.H. van
Colbers, A.P.
Guchelaar (LUMC), H.J.
Erp, N. van
Hartigh, J. den
Burger, D.M.
Laarhoven, H.W. van

January 2015

BACKGROUND: The effect of tamoxifen dose elevation on endoxifen serum concentration was investigated...

CYP2D6 genotype and adjuvant tamoxifen:meta-analysis of heterogeneous study populations

Province, M. A.
Goetz, M. P.
Brauch, H.
Flockhart, D. A.
Hebert, J. M.
Whaley, R.
Suman, V. J.
Schroth, W.
Winter, S.
Zembutsu, H.
Mushiroda, T.
Newman, W. G.
Lee, M-T M.
Ambrosone, C. B.
Beckmann, M. W.
Choi, J-Y
Dieudonné, A-S
Fasching, P. A.
Ferraldeschi, R.
Gong, L.
Haschke-Becher, E.
Howell, A
Jordan, L. B.
Hamann, U.
Kiyotani, K.
Krippl, P.
Lambrechts, D.
Latif, A
Langsenlehner, U.
Lorizio, W.
Neven, P.
Nguyen, A. T.
Park, B-W
Purdie, C. A.
Quinlan, P.
Renner, W.
Schmidt, M.
Schwab, M.
Shin, J-G
Stingl, J. C.
Wegman, P.
Wingren, S.
Wu, A. H. B.
Ziv, E.
Zirpoli, G.
Thompson, A. M.
Jordan, V. C.
Nakamura, Y.
Altman, R. B.
Ames, M. M.
Weinshilboum, R. M.
Eichelbaum, M.
Ingle, J. N.
Klein, T. E.

February 2014

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy r...

CYP2D6 genotype and adjuvant tamoxifen:meta-analysis of heterogeneous study populations

Province, M. A.
Goetz, M. P.
Brauch, H.
Flockhart, D. A.
Hebert, J. M.
Whaley, R.
Suman, V. J.
Schroth, W.
Winter, S.
Zembutsu, H.
Mushiroda, T.
Newman, W. G.
Lee, M-T M.
Ambrosone, C. B.
Beckmann, M. W.
Choi, J-Y
Dieudonné, A-S
Fasching, P. A.
Ferraldeschi, R.
Gong, L.
Haschke-Becher, E.
Howell, A
Jordan, L. B.
Hamann, U.
Kiyotani, K.
Krippl, P.
Lambrechts, D.
Latif, A
Langsenlehner, U.
Lorizio, W.
Neven, P.
Nguyen, A. T.
Park, B-W
Purdie, C. A.
Quinlan, P.
Renner, W.
Schmidt, M.
Schwab, M.
Shin, J-G
Stingl, J. C.
Wegman, P.
Wingren, S.
Wu, A. H. B.
Ziv, E.
Zirpoli, G.
Thompson, A. M.
Jordan, V. C.
Nakamura, Y.
Altman, R. B.
Ames, M. M.
Weinshilboum, R. M.
Eichelbaum, M.
Ingle, J. N.
Klein, T. E.

February 2014

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy r...

CYP2D6 genotype and adjuvant tamoxifen:meta-analysis of heterogeneous study populations

Province, M. A.
Goetz, M. P.
Brauch, H.
Flockhart, D. A.
Hebert, J. M.
Whaley, R.
Suman, V. J.
Schroth, W.
Winter, S.
Zembutsu, H.
Mushiroda, T.
Newman, W. G.
Lee, M-T M.
Ambrosone, C. B.
Beckmann, M. W.
Choi, J-Y
Dieudonné, A-S
Fasching, P. A.
Ferraldeschi, R.
Gong, L.
Haschke-Becher, E.
Howell, A
Jordan, L. B.
Hamann, U.
Kiyotani, K.
Krippl, P.
Lambrechts, D.
Latif, A
Langsenlehner, U.
Lorizio, W.
Neven, P.
Nguyen, A. T.
Park, B-W
Purdie, C. A.
Quinlan, P.
Renner, W.
Schmidt, M.
Schwab, M.
Shin, J-G
Stingl, J. C.
Wegman, P.
Wingren, S.
Wu, A. H. B.
Ziv, E.
Zirpoli, G.
Thompson, A. M.
Jordan, V. C.
Nakamura, Y.
Altman, R. B.
Ames, M. M.
Weinshilboum, R. M.
Eichelbaum, M.
Ingle, J. N.
Klein, T. E.

February 2014

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy r...

The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity

Welzen, MEB
Dezentje, VO
van Schaik, Ron
Colbers, APH
Guchelaar, HJ
van Erp, NP
den Hartigh, J
Burger, DM
van Laarhoven, HWM

January 2015

Background: The effect of tamoxifen dose elevation on endoxifen serum concentration was investigated...

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects

Dezentjé, V O
Opdam, F L
Gelderblom, H
Hartigh den, J
Van der Straaten, T
Vree, R
Maartense, E
Smorenburg, C H
Putter, H
Dieudonné, A S
Neven, Patrick
Van de Velde, C J H
Nortier, J W R
Guchelaar, H-J

October 2015

Breast cancer patients with absent or reduced CYP2D6 activity and consequently low endoxifen levels ...

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations

박병우

January 2014

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy r...

Effect of genetic variability in 20 pharmacogenes on concentrations of tamoxifen and its metabolites

Chen, Yuanhuang
Marcath, Lauren A.
Eliassen, Finn Magnus
Lende, Tone Hoel
Soiland, Havard
Mellgren, Gunnar
Helland, Thomas
Hertz, Daniel Louis

January 2021

Background: Tamoxifen, as a treatment of estrogen receptor positive (ER+) breast cancer, is a weak a...

Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping

Binkhorst, Lisette
Mathijssen, Ron
Jager, Agnes
Gelder, Teun

January 2015

Clinical response to tamoxifen varies widely among women treated with this drug for hormone receptor...

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

Abstract

Extracted data

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

Abstract

Extracted data

Related items

Related items